If you have been reading about DAC and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-05-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
TsrM in thiostrepton biosynthesis PoyD and PoyC in polytheonamide biosynthesis TbtI in thiomuracin biosynthesis NosN in nosiheptide biosynthesis EpeE (previously called YydG) in epipeptide biosynthesis MoaA in molybdopterin biosynthesis PqqE in pyrroloquinoline quinone biosynthesis TunB in tunicamycin biosynthesis OxsB in oxetanocin biosynthesis BchE in anaerobic bacteriochlorophyll biosynthesis F0 synthases in F420 cofactor biosynthesis MqnE and MqnC in menaquinone biosynthesis QhpD in post-translational processing of quinohemoprotein amine dehydrogenase RumMC2 in ruminococcin C biosynthesis
From April to May 2024, Rio Grande do Sul was hit by massive flooding, which also severely hit Porto Alegre. This was partly seen as, in addition to the sheer amount of precipitation, insufficient pumping of water, as trash and rubble had blocked many manholes in the city. Melo, during the flooding, affirmed that the city government knew that there was a possibility of strong rains and was not taken by surprise. He denied, however, that the city government had delayed its response and put the responsibility on the new round of floodings for the high volume, as well as the population, blaming them for the trash strewn throughout the city. During the floods, the Guaíba hit its highest ever historical level, leaving various parts of the city submerged and many people stranded. Due to the severity of the situation, the municipality set up 21 centers to receive thousands of people who were forced to leave their homes. The flooding was also marked by conflicts between Melo and the federal government, during which he criticized what he saw was the lack of support from them, despite having also delayed a formal emergency request for days. During this period, federal deputy Fernanda Melchionna and city councilman Roberto Robaina, both from PSOL, sued Melo. They both requested that the State Attorney's Office to start an investigation against Melo due to the fact that the municipal government had not sent the federal government the data of families in Porto Alegre hit by the floods.
The two yeast genera; Pichia (sensu lato) and Saccharomyces, have similar growth conditions and tolerances; thus, the culture of Komagataella can be adopted by labs without many modifications. Moreover, unlike S. cerevisiae, Komagataella has the ability to functionally process proteins with large molecular weight, which is useful in a translational host. Considering all the advantages, Komagataella can be usefully employed as both a genetic and experimental model organism.
OXT was negatively and significantly correlated with HbA1c, FGF21, HGF and positively correlated with both irisin and gender. OXT levels higher in normoglycemic as compared to pre-DM/T2DM patients. OXT are reduced in patient with pre-DM/Type2 DM.
Sources: en.wikipedia.org
Clinical identification of P. aeruginosa may include identifying the production of both pyocyanin and fluorescein, as well as its ability to grow at 42 °C. P. aeruginosa is capable of growth in diesel and jet fuels, where it is known as a hydrocarbon-using microorganism, causing microbial corrosion. It creates dark, gellish mats sometimes improperly called "algae" because of their appearance.
==== Predicting flood plain formation ==== By plotting stream power along the length of a river course as a second-order exponential curve, you are able to identify areas where flood plains may form and why they will form there.
== Controversy == Carlisle drew controversy when the Nine Network's television program A Current Affair broadcast footage on 21 October 2015, the same day he was traded to St Kilda, of a man suspected to be Carlisle snorting a white substance. A statement released the following morning by Carlisle confirmed it was him in the footage and he admitted that he had "made a very poor decision" and was "truly sorry". In November, he received a strike under the AFL illicit drugs policy, a two-match suspension for the start of the 2016 season (which was served concurrently with his season-long ban arising from the supplements scandal), and forfeited $50,000 in marketing money.
Sources: en.wikipedia.org
The light source is shone into the sample and focused into a slit The transmitted light is refracted into a rainbow with the reflection grating The resulting light strikes the photodetector device which compares the intensity of the beam Electronic circuits convert the relative currents into linear transmission percentages and/or absorbance/concentration values Many older spectrophotometers must be calibrated by a procedure known as "zeroing", to balance the null current output of the two beams at the detector. The transmission of a reference substance is set as a baseline (datum) value, so the transmission of all other substances is recorded relative to the initial "zeroed" substance. The spectrophotometer then converts the transmission ratio into 'absorbency', the concentration of specific components of the test sample relative to the initial substance.
=== Limitations of non-invasive electrical and magnetic methods === Brain tissue stimulation using non-invasive electrical and magnetic methods raises several concerns, including the following: The first issue is the uncertain dose for healthy stimulation. While neurophysiology lacks knowledge about the nature of such a treatment of nervous diseases at the cellular level, non-invasive electrical and magnetic therapies involve excessive exposure of the brain to an intense field, which is several times and even orders of magnitude higher than natural electromagnetic fields in the brain. Another significant challenge of non-invasive electrical and magnetic methods is to localize the effect of stimulation on specific neuronal networks that need to be treated. We still need to gain knowledge about mental processes at the cellular level. Neuronal correlates of cognitive functions are still intriguing questions for contemporary research. Non-invasive electrical and magnetic brain tissue stimulation targets a large area of poorly characterized tissue. Therefore, it is unclear whether electrical and magnetic fields reach only the neuronal networks of the brain that need treatment. Again, these methods involve excessive exposure to intense electrical and magnetic fields several times and even orders of magnitude higher than natural ones in the brain. However, non-invasive electrical and magnetic brain tissue methods cannot target only the neuronal networks that need to be treated. The undefined radiation target can destroy healthy cells during therapy.
The four substrates of this enzyme are orthanilic acid, reduced nicotinamide adenine dinucleotide (NADH), oxygen and a proton. Its products are 2,3-dihydroxybenzenesulfonic acid, oxidised NAD+, and ammonia. This enzyme is an oxidoreductase that uses molecular oxygen as oxidant and incorporates both its atoms into the starting material. The systematic name of its class is 2-aminobenzenesulfonate,NADH:oxygen oxidoreductase (2,3-hydroxylating, ammonia-forming). It is also called 2-aminosulfobenzene 2,3-dioxygenase. It can degrade a variety of benzenesulfonic acids.
== Clinical use == Tylosin has been used to treat a variety of different diseases throughout the world. Differing formulations and licensing conditions mean it may not be a recognized method of treatment for certain conditions in certain countries. In general, tylosin is licensed for the treatment of infections caused by organisms susceptible to the drug, but it has also been used as a treatment of colitis in small animals, as a growth promotant in food-producing animals, and as a way of reducing epiphora (tear staining) around the eyes of white-faced dogs. In these cases, the result is positive only when using the tylosin in the form of tartrate, a chelating porphyrin. No marketing authority exists for the use of other tylosin forms as a tear-stain remover, thus it is not legal to use it for such purposes; the exception is as a prescription-only medicine of last resort by veterinarians under the cascading rule (UK) or the extra-label use rule (US). Examples of bacterial infections that could potentially be treated with tylosin include respiratory infections, metritis, and acute mastitis in cattle; mastitis in sheep and goats; enteritis, pneumonia, erysipelas, and infectious arthritis in swine; and soft-tissue infections in small animals. While tylosin may be one appropriate therapeutic choice in theory for the conditions listed above, many other antibiotics may be preferable for treating a specific infection, and tylosin will not be the first choice. It is also used as a growth promoter for a variety of terrestrial and aquatic animals grown for human consumption.
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.